US4559222A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Matrix composition for transdermal therapeutic system
Assignee: Alza Corp
•
Filing: 1983-05-04
•
Granted: 1985-12-17
•
Expires: 2003-05-04
Abstract
Abstract Mineral oil (MO) polyisobutylene (PIB), colloidal silicon dioxide (CSD) mixtures suitable for use as drug containing matrices in transdermal delivery systems are disclosed. Preferred systems for dispensing moderately mineral oil soluble drugs contain at least about 6% CSD, have a MO/PIB of at least 1.0 and a viscosity of at least 1.5x107 poises. Preferred systems for dispensing clonidine have a clonidine permeability of at least 1.0x10-4 mu g/cm sec and a MO/PIB of at least 1.2.
Inventors
- 👤 David J. Enscore
- 👤 Robert M. Gale
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K35/00; A61K35/02; A61K35/08; A61K9/7084
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
52 words
A composition of matter suitable for use as a matrix in a drug delivery system comprising mineral oil, polyisobutylene, a moderately mineral oil soluble drug and at least 6% colloidal silicon dioxide, the MO/PIB ratio being at least 1.0, and being characterized by having a viscosity of at least 1.5×10 7 poise.
Claim 2
Dependent Claim
52 words
A composition of matter suitable for use as a matrix in a drug delivery system comprising mineral oil, polyisobutylene, a moderately mineral oil soluble drug and at least 6% colloidal silicon dioxide, the MO/PIB ratio being at least 1.0, and being characterized by having a viscosity of at least 1.5×10 7 poise.
Claim 3
Dependent Claim
21 words
The composition of claim 1 wherein said moderately mineral oil soluble drug is dispersed therethrough in amounts up to about 40%.
Claim 4
Dependent Claim
26 words
The composition of claim 2 wherein said drug is present at a level between the saturation concentration of said drug in the composition and about 20%.
Claim 5
Dependent Claim
29 words
The composition of claim 3 wherein the ratio of mineral oil to polyisobutylene is at least 1.2 and the composition contains at least 7.5% by weight colloidal silicon dioxide.
Claim 6
Dependent Claim
33 words
The composition of claim 4 wherein said drug is selected from the group consisting of clonidine, scopolamine, propranolol, estradiol, phenylpropanolamine, ouabain, salbutamol, guanabenz, labetolol, atropine, haloperidol, bromocryptine, chloropheniramine, metrifonate, isosorbide dinitrate and nitroglycerin.
Claim 7
Dependent Claim
25 words
The composition of claim 1 wherein said drug is clonidine and the permeability of the composition to clonidine is at least 1.0×10 -4 μg/cm sec.
Claim 8
Dependent Claim
14 words
The composition of claim 6 wherein the value of MO/PIB is at least 1.2.
Claim 9
Dependent Claim
112 words
In a transdermal therapeutic system, comprising a drug reservoir layer and an adhesive layer, a moderately mineral oil soluble drug dispersed in at least said reservoir layer at a concentration above the saturation concentration of said drug in said layer and a drug release rate release controlling membrane disposed between said reservoir and adhesive, said reservoir and said adhesive layer comprising a mixture of mineral oil and polyisobutylene, the improvement wherein said reservoir and said adhesive layer contain at least about 6% colloidal silicon dioxide, have a viscosity of at least 1.5×10 7 poise and and a ratio of mineral oil to polyisobutylene in the reservoir and adhesive of at least 1.2.
Claim 10
Dependent Claim
112 words
In a transdermal therapeutic system, comprising a drug reservoir layer and an adhesive layer, a moderately mineral oil soluble drug dispersed in at least said reservoir layer at a concentration above the saturation concentration of said drug in said layer and a drug release rate release controlling membrane disposed between said reservoir and adhesive, said reservoir and said adhesive layer comprising a mixture of mineral oil and polyisobutylene, the improvement wherein said reservoir and said adhesive layer contain at least about 6% colloidal silicon dioxide, have a viscosity of at least 1.5×10 7 poise and and a ratio of mineral oil to polyisobutylene in the reservoir and adhesive of at least 1.2.
Claim 11
Dependent Claim
31 words
The transdermal therapeutic system of claim 8 wherein said release rate controlling membrane contains mineral oil and the overall ratio of MO/PIB in the transdermal therapeutic system is at least 1.4
Claim 12
Dependent Claim
35 words
The transdermal therapeutic system of claim 9 wherein said drug is selected from the group consisting of clonidine, scopolamine, propranolol, estradiol, phenylpropanolamine, ouabain, salbutamol, guanabenz, labetolol, atropine, haloperidol, bromocryptine, chloropheniramine, metrifonate, isosorbide dinitrate and nitroglycerin.
Claim 13
Dependent Claim
32 words
The system of claim 9 wherein said drug is clonidine and the in vitro drug release rate from the system to an infinite sink is at least B 2.0 μg/cm 2 hr.
Claim 14
Dependent Claim
55 words
In a drug containing matrix composition consisting of a gel of mineral oil and polyisobutylene having a moderately mineral oil-soluble drug dispersed therethrough, the improvement wherein said composition has at least about 6.0% colloidal silicon dioxide dispersed therethrough, an MO/PIB ratio of at least 1.0 and a viscosity of at least about 1.5×10 7 poise.
Claim 15
Dependent Claim
55 words
In a drug containing matrix composition consisting of a gel of mineral oil and polyisobutylene having a moderately mineral oil-soluble drug dispersed therethrough, the improvement wherein said composition has at least about 6.0% colloidal silicon dioxide dispersed therethrough, an MO/PIB ratio of at least 1.0 and a viscosity of at least about 1.5×10 7 poise.
Claim 16
Dependent Claim
47 words
The matrix composition of claim 11 wherein said MO/PIB ratio is at least about 1.2, the colloidal silicon dioxide is present in amounts of between 6 and 10% and said drug is present in an amount no less than saturation concentration and no greater than about 40%.
Claim 17
Dependent Claim
25 words
The composition of claim 12 wherein said drug is clonidine and the permeability of the matrix to clonidine is at least 1×10 -4 μg/cm sec.
Claim 18
Dependent Claim
22 words
The composition of claim 1 wherein said polyisobutylene has an average molecular weight in the range of about 35,000 to about 1,500,000.
Claim 19
Dependent Claim
21 words
The composition of claim 5 wherein said polyisobutylene has an average molecular weight in the range of about 35,000 to 1,500,000.
Claim 20
Dependent Claim
21 words
The composition of claim 7 wherein said polyisobutylene has an average molecular weight in the range of about 35,000 to 1,500,000.
Claim 21
Dependent Claim
21 words
The composition of claim 13 wherein said polyisobutylene has an average molecular weight in the range of about 35,000 to 1,500,000.
References Cited (Backward Citations)
US2627938A
Cited
US2628205A
Cited
US2775561A
Cited
US3029188A
Cited
US3079299A
Cited
US3250680A
Cited
US3293205A
Cited
US3215599A
Cited
US3400197A
Cited
US3574827A
Cited
US3733403A
Cited
GB2021950A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-12-16 | 1989-06-17 | 1989-12-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-12-16 | 1993-06-17 | 1993-12-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-12-16 | 1997-06-17 | 1997-12-17 | $7700.00 | Window Closed / Lapsed |